China Blood Product Industry Report, 2012-2015
  • Jul./2013
  • Hard Copy
  • USD $2,500
  • Pages:116
  • Single User License
    (PDF Unprintable)       
  • USD $2,400
  • Code: ZYM042
  • Enterprise-wide License
    (PDF Printable & Editable)       
  • USD $3,700
  • Hard Copy + Single User License
  • USD $2,700
Plasma is a key raw material of the blood product industry. In August 2011, China shut down 16 plasma stations in Guizhou, resulting in a decrease of 15% in the plasma volume of the year. However, due to the implementation of favorable policies, widening gap between supply and demand, rising product prices and other factors, more than 150 plasma stations in China produced about 3,600 tons of plasma in 2012, up 14.2% year on year. From 2012 to mid-2013, new plasma stations of some Chinese enterprises have started plasma collection or obtained plasma collection permits, such as Yuechi plasma station of Jiangxi Boya Bio-Pharmaceutical, Changyuan plasma station of Hualan Bio, and Caoxian plasma station of China Biologic Products. It’s expected that China’s plasma supply tension will be further eased after 2013.

According to the lot release statistics of National Institutes for Food and Drug Control, in the first ten months of 2012, China’s total lot release volume of blood products was about 36.13 million bottles, an increase of 7.1% compared with the full year of 2011. In addition, except human coagulation factor VIII with a decreased lot release volume, other products saw growing release volume. In particular, human immunoglobulin, tetanus immunoglobulin, human fibrinogen, imported human serum albumin witnessed higher growth rates of 321%, 95%, 79%, 45% respectively in the first ten months of 2012. However, Chinese blood product enterprises have weak R&D capability, low plasma utilization and fewer product varieties. The domestic market is still dominated by technically undemanding human serum albumin and human immunoglobulin (ph4) for intravenous injection, which accounted for more than 60% of the lot release volume in 2012.

In order to ease the domestic shortage of blood products, China has allowed the import of human serum albumin and recombinant coagulation factor VIII in recent years. Human serum albumin imports have grown rapidly due to low prices. The lot release volume was 8.51 million bottles in the first ten months of 2012, occupying 47.5% of the lot release volume of such products (43.3% in 2011); Behring, Baxter, Instituto Grifols and Octapharma were top four companies by lot release volume. However, due to high prices and national policy restrictions, the import of recombinant coagulation factor VIII is very small, only Bayer and Baxter products were allowed to be imported as of the end of 2012.

China Blood Product Industry Report, 2012-2015 covers the followings:

20120114.gif?Plasma volume, plasma station distribution, market size and supply & demand of China blood product industry;
20120114.gif Competition pattern, policy environment and import & export of China blood product industry;
20120114.gif Market supply & demand and competition pattern of eight categories of blood products including human serum albumin, human immunoglobulin (ph4) for intravenous injection, coagulation factors in China;
20120114.gif Development, operation, plasma stations and lot release volume of 12 local blood product producers in China.

As of the end of 2012, there were about 30 enterprises passing GMP certification and in normal operation, among them, only Hualan Bio, Tiantan Biological Products (including Chengdu Ronsen), Shanghai RAAS, Yuanda Shuyang Pharmaceutical, China Biologic Products have an annual plasma volume of over 300 tons. In 2012, the five enterprises accounted for 56.1% of China’s total plasma volume, and about 30% of China’s blood product market revenue.

Guangdong Shuanglin Bio-pharmacy, the sixth place holder, had nine plasma stations (three under construction) in 2012, with a plasma volume of about 247 tons and blood product revenue of RMB 431 million. The company has held the largest lot release volume of rabies immunoglobulin in recent years. Jiangxi Boya, though occupying a small market share (1.8% in 2012 by sales), has seven plasma stations, with output and sales volume expected to be further enhanced in the future.
1. Profile of Blood Products
1.1 Definition
1.2 Classification
1.3 Recombinant Blood Products
1.4 Industry Chain
1.5 Features

2. Overview of China Blood Products Industry
2.1 Market Size
2.2 Development Status
2.3 Supply & Demand
2.3.1 Supply 
2.3.2 Demand 
2.4 Market Competition
2.5 Operating Environment
2.5.1 International Market
2.5.2 Policies
2.5.3 Domestic Biopharmaceutical Market
2.6 Import & Export

3. Blood Product Market Segments in China
3.1 Human Albumin
3.1.1 Supply & Demand
3.1.2 Competition Pattern
3.1.3 Prospects
3.2 Human Immunoglobulin (pH4) for Intravenous Injection
3.2.1 Supply & Demand
3.2.2 Competition Pattern
3.3 Coagulation Factor VIII
3.3.1 Supply & Demand
3.3.2 Competition Pattern
3.3.3 Prospects
3.4 Hepatitis B Immunoglobulin
3.4.1 Supply & Demand
3.4.2 Competition Pattern
3.5 Human Immunoglobulin
3.5.1 Supply & Demand
3.5.2 Competition Pattern
3.6 Human Prothrombin Complex
3.6.1 Supply & Demand
3.6.2 Competition Pattern
3.7 Tetanus Immunoglobulin
3.7.1 Supply & Demand
3.7.2 Competition Pattern
3.8 Rabies Immunoglobulin
3.8.1 Supply & Demand
3.8.2 Competition Pattern

4. Key Companies in China
4.1 China Biologic Products Inc.
4.1.1 Profile
4.1.2 Operation
4.1.3 Revenue Structure
4.1.4 Clients and Suppliers
4.1.5 R&D and Investment
4.1.6 Shandong Taibang Biological Products Co., Ltd.
4.1.7 Guiyang Qianfeng Biological Products Co., Ltd.
4.1.8 Xi’an Hui Tian Blood Products Co., Ltd.
4.1.9 Development and Prospects
4.2 Hualan Biological Engineering Inc.
4.2.1 Profile
4.2.2 Operation
4.2.3 Revenue Structure
4.2.4 Gross Margin
4.2.5 Clients and Suppliers
4.2.6 R&D and Investment
4.2.7 Blood Products
4.2.8 Development and Prospects
4.3 Shanghai RAAS Blood Products Co., Ltd.
4.3.1 Profile
4.3.2 Operation
4.3.3 Revenue Structure
4.3.4 Gross Margin
4.3.5 Clients and Suppliers
4.3.6 R&D and Investment
4.3.7 Development and Prospects
4.4 Beijing Tiantan Biological Products Co., Ltd.
4.4.1 Profile
4.4.2 Operation
4.4.3 Revenue Structure
4.4.4 Clients and Suppliers
4.4.5 Gross Margin
4.4.6 R&D and Investment
4.4.7 Blood Products (Chengdu Ronsen Pharmaceutical Co., Ltd.)
4.4.8 Development and Prospects
4.5 Zhenxing Biopharmaceutical & Chemical Inc.
4.5.1 Profile
4.5.2 Operation
4.5.3 Revenue Structure
4.5.4 Gross Margin
4.5.5 Clients and Suppliers
4.5.6 R&D and Investment
4.5.7 Blood Products (Guangdong Shuanglin Bio-Pharmacy Co., Ltd.)
4.5.8 Development and Prospects
4.6 Jiangxi Boya Biopharmaceutical Co., Ltd.
4.6.1 Profile
4.6.2 Operation
4.6.3 Revenue Structure
4.6.4 Gross Margin
4.6.5 Clients and Suppliers
4.6.6 R&D and Investment
4.6.7 Development and Prospects
4.7 Sichuan Yuanda Shuyang Pharmaceutical Co., Ltd.
4.7.1 Profile
4.7.2 Blood Products
4.8 CNBG Shanghai Institute of Biological Products
4.8.1 Profile
4.8.2 Blood Products
4.9 Shanxi Kangbao Biological Product Co., Ltd.
4.9.1 Profile
4.9.2 Blood Products
4.10 Green Cross
4.10.1 Profile
4.10.2 Blood Products
4.11 Humanwell Healthcare (Group) Co., Ltd.
4.11.1 Profile
4.11.2 Operation
4.11.3 Blood Products (Wuhan Zhongyuan Ruide Biological Products Co., Ltd.)
4.12 Walvax Biotechnology Co, Ltd.
4.12.1 Profile
4.12.2 Operation
4.12.3 Blood Products (Hebei Daan Pharmaceutical Co., Ltd.)
Basic Composition of Blood
Classification and Application of Blood Products
Comparison between Recombinant Blood Products and Conventional Blood Products
Classification and Comparison of Domestic and Foreign Recombinant Blood Products
Blood Product Industry Chain 
China’s Blood Product Market Size, 2003-2015E
Prices of Some Blood Products in China, 2013 
Lot Release Volume of Blood Products in China (by Product), 2007-2012 
China’s Blood Product Structure (by Lot Release Volume), 2009-2012 
China’s Plasma Volume, 2002-2012 
Plasma Station Distribution in China by Region, Jun 2013
Health Insurance Coverage of Mainstream Blood Products in China
Comparison between China and Developed Countries by Per Capita Consumption of Blood Products 
Plasma Station Distribution, Plasma Volume and Blood Product Revenue of Major Blood Product Enterprises in China, 2012 
Comparison among Domestic Blood Product Producers by Product Line
Global Blood Product Structure
Blood Products Available in Foreign Markets
Ongoing Clinical Trials of New Indications in Foreign Countries 
Global Producers of Blood Products 
Main Policies for Blood Products in China 
Industrial Sales Output Value and Total Profit of China’s Biological and Biochemical Manufacturing Industry, 2008-2012 
Human Serum Albumin Prices in China, 2003-2012
Domestic and Imported Human Serum Albumin in China (by Lot Release Volume), 2007-2012 
Market Share of Major Producers of Human Serum Albumin in China (by Lot Release Volume), 2008-2012 
Comparison between China and USA by Consumption of Human Immunoglobulin for Intravenous Injection, 2010 
Lot Release Volume and Growth Rate of Human Immunoglobulin (pH4) for Intravenous Injection in China, 2007-2012
Comparison between China and Other Countries by Price of Human Immunoglobulin (pH4) for Intravenous Injection
Market Share of Major Producers of Human Immunoglobulin (pH4) for Intravenous Injection in China (by Lot Release Volume), 2007-2012 
Lot Release Volume and Growth Rate of Coagulation Factor VIII in China, 2008-2012 
Market Share of Human Coagulation Factor VIII Producers in China (by Lot Release Volume), 2008-2012 
Comparison between Human-derived Coagulation Factor VIII and Recombinant Coagulation Factor VIII
Lot Release Volume and Growth Rate of Hepatitis B Immunoglobulin in China, 2008-2012 
Market Share of Major Hepatitis B Immunoglobulin Enterprises in China (by Lot Release Volume), 2008-2012 
Prices of Human Immunoglobulin in China by Dosage Form, 2013
Lot Release Volume and Growth Rate of Human Immunoglobulin in China, 2008-2012 
Market Share of Major Human Immunoglobulin Enterprises in China (by Lot Release Volume), 2008-2012 
Lot Release Volume and Growth Rate of Human Prothrombin Complex in China, 2009-2012 
Market Share of Human Prothrombin Complex Enterprises in China (by Lot Release Volume), 2008-2012 
Lot Release Volume and Growth Rate of Tetanus Immunoglobulin in China, 2008-2012 
Market Share of Major Tetanus Immunoglobulin Enterprises in China (by Lot Release Volume), 2008-2012 
Lot Release Volume and Growth Rate of Rabies Immunoglobulin in China, 2008-2012 
Market Share of Major Rabies Immunoglobulin Enterprises in China (by Lot Release Volume), 2008-2012 
Shareholding Structure of China Biologic Products, 2012 
Revenue and Operating Income of China Biologic Products, 2007-2012 
Revenue of China Biologic Products (by Product), 2011-2012 
Revenue Structure of China Biologic Products (by Product), 2010-2012 
Revenue Contribution and % of Total Revenue of China Biologic Products’ Top Five Customers, 2008-2012 
R&D Investment and % of Revenue of China Biologic Products, 2010-2012 
New Products under Research by China Biologic Products, 2012
Lot Release Volume of Blood Products of Shandong Taibang, 2008-2012 
Lot Release Volume of Blood Products of Guiyang Qianfeng, 2007-2011 
Lot Release Volume of Blood Products of Xi’an Hui Tian, 2008-2012 
Revenue and Operating Income of China Biologic Products, 2012-2015 
Revenue and Total Profit of Hualan Biological Engineering, 2007-2012 
Revenue of Hualan Biological Engineering (by Sector), 2007-2012 
Revenue of Hualan Biological Engineering (by Product), 2007-2012 
Revenue of Hualan Biological Engineering (by Region), 2007-2012 
Gross Margin of Hualan Biological Engineering (by Sector), 2007-2012 
Gross Margin of Hualan Biological Engineering (by Product), 2007-2012 
Revenue Contribution and % of Total Revenue of Hualan Biological Engineering’s Top Five Customers, 2007-2012 
Procurement of Hualan Biological Engineering from Top Five Suppliers, 2007-2012 
R&D Investment and % of Total Revenue of Hualan Biological Engineering, 2007-2012 
Blood Product Types and Specifications of Hualan Biological Engineering 
Plasma Collection Distribution of Hualan Biological Engineering, May 2013
Lot Release Volume of Blood Products of Hualan Biological Engineering, 2008-2012 
Blood Product Revenue and Gross Margin of Hualan Biological Engineering, 2007-2012 
Blood Product Revenue and Gross Margin of Hualan Biological Engineering (by Product), 2007-2012 
Revenue and Operating Income of Hualan Biological Engineering, 2012-2015E 
Plasma Station Distribution of Shanghai RAAS, 2012
Revenue and Operating Income of Shanghai RAAS, 2007-2012 
Lot Release Volume of Blood Products of Shanghai RAAS, 2008-2012 
Revenue of Shanghai RAAS (by Product), 2007-2012 
Revenue of Shanghai RAAS (by Region), 2007-2012 
Gross Margin of Shanghai RAAS (by Product), 2007-2012 
Revenue Contribution of Shanghai RAAS’ Top Five Customers, 2007-2012 
Name List and Revenue Contribution of Shanghai RAAS’ Top Five Customers, 2012 
Procurement of Shanghai RAAS from Top Five Suppliers, 2007-2012 
R&D Costs and % of Revenue of Shanghai RAAS, 2007-2012 
Revenue and Operating Income of Shanghai RAAS, 2012-2015E 
Major Subsidiaries and Their Revenue and Net Income of Beijing Tiantan Biological Products, 2012 
Revenue and Total Profit of Beijing Tiantan Biological Products, 2007-2012 
Revenue of Beijing Tiantan Biological Products (by Sector), 2007-2012 
Revenue of Beijing Tiantan Biological Products (by Region), 2007-2012 
Gross Margin of Beijing Tiantan Biological Products (by Sector), 2007-2012 
Procurement of Beijing Tiantan Biological Products from Top Five Suppliers, 2007-2012 
Revenue Contribution and % of Total Revenue of Beijing Tiantan Biological Products’ Top Five Customers, 2007-2012 
Name List and Revenue Contribution of Beijing Tiantan Biological Products’ Top Five Customers, 2012 
R&D Costs and % of Revenue of Beijing Tiantan Biological Products, 2009-2012 
Plasma Station Distribution of Beijing Tiantan Biological Products, 2012
Blood Product Revenue and Gross Margin of Beijing Tiantan Biological Products, 2007-2012 
Lot Release Volume of Blood Products of Chengdu Ronsen and Tiantan Chongqing, 2008-2012 
Revenue and Operating Income of Beijing Tiantan Biological Products, 2012-2015 
Revenue and Operating Income of Zhenxing Biopharmaceutical & Chemical, 2009-2012 
Operating Revenue of Zhenxing Biopharmaceutical & Chemical (by Product), 2009-2012 
Operating Revenue of Zhenxing Biopharmaceutical & Chemical (by Region), 2009-2012 
Gross Margin of Zhenxing Biopharmaceutical & Chemical (by Product), 2009-2012 
Revenue Contribution of Zhenxing Biopharmaceutical & Chemical’s Top Five Customers, 2009-2012 
Name List and Revenue Contribution of Zhenxing Biopharmaceutical & Chemical’s Top Five Customers, 2012 
Procurement of Zhenxing Biopharmaceutical & Chemical from Top Five Suppliers, 2012 
R&D Costs and % of Revenue of Zhenxing Biopharmaceutical & Chemical, 2009-2012 
R&D Progress of Zhenxing Biopharmaceutical & Chemical, 2012 
Plasma Volume of Shuanglin Bio-pharmacy, 2010-2012 
Plasma Station Distribution of Shuanglin Bio-pharmacy, 2012
Blood Product Output, Sales Volume and Inventory of Zhenxing Biopharmaceutical & Chemical, 2011-2012 
Lot Release Volume of Blood Products of Shuanglin Bio-pharmacy, 2008-2012 
Blood Product Revenue and Gross Margin of Zhenxing Biopharmaceutical & Chemical, 2009-2012 
Revenue and Operating Income of Zhenxing Biopharmaceutical & Chemical, 2012-2015E
Plasma Collection Volume of Jiangxi Boya Bio-pharmaceutical, 2008-2012 
Revenue and Operating Income of Jiangxi Boya Bio-pharmaceutical, 2009-2012 
Revenue of Jiangxi Boya Bio-pharmaceutical (by Product), 2009-2012 
Lot Release Volume of Blood Products of Jiangxi Boya Bio-pharmaceutical, 2011-2012 
Revenue of Jiangxi Boya Bio-pharmaceutical (by Region), 2009-2012 
Gross Margin of Jiangxi Boya Bio-pharmaceutical (by Product), 2009-2012 
Revenue Contribution and % of Total Revenue of Jiangxi Boya Bio-pharmaceutical’s Top Five Customers, 2009-2012 
Name List and Revenue Contribution of Jiangxi Boya Bio-pharmaceutical’s Top Five Customers, 2012 
Procurement of Jiangxi Boya Bio-pharmaceutical from Top Five Suppliers, 2009-2012 
R&D Costs and % of Revenue of Jiangxi Boya Bio-pharmaceutical, 2009-2012 
Revenue and Operating Income of Jiangxi Boya Bio-pharmaceutical, 2012-2015E
Plasma Station Distribution of Sichuan Yuanda Shuyang Pharmaceutical, 2012 
Lot Release Volume of Blood Products of Sichuan Yuanda Shuyang Pharmaceutical, 2008-2012 
Lot Release Volume of Blood Products of CNBG Shanghai Institute of Biological Products, 2008-2012 
Plasma Station Distribution of CNBG Shanghai Institute of Biological Products, 2012
Plasma Station Distribution of Shanxi Kangbao Biological Product, 2012
Lot Release Volume of Blood Products of Shanxi Kangbao Biological Product, 2008-2012
Plasma Station Distribution of Green Cross China, 2012
Lot Release Volume of Blood Products of Green Cross China, 2008-2012 
Revenue and Operating Income of Humanwell Healthcare, 2007-2012 
Lot Release Volume of Blood Products of Wuhan Zhongyuan Ruide Biological Products, 2008-2012
Industrial Distribution of Walvax Biotechnology
Revenue and Operating Income of Walvax Biotechnology, 2007-2012 

China Animal Vaccine Industry Report, 2019-2025

Chinese animal vaccine industry showed a CAGR of 8% between 2013 and 2017, but it was depressed by the outbreak of African Swine Fever in 2018 with the market size edging down 2.5% on an annualized ba...

China Blood Product Industry Report, 2020-2026

With the dynamic adjustment in the catalog of medicines covered by national medical insurance system, the scope of clinical use of almost all blood products grows tremendously, so does the reimburseme...

China Vacuum Blood Collection Device Industry Report, 2019-2025

As laboratory medicine advances, favorable polices are issued and people live a better life and care more about their health, vacuum blood collection systems get increasingly used. In 2018, global vac...

China Human Vaccine Industry Report, 2019-2025

China has been the world’s biggest producer and consumer of human vaccines over four decades of planned vaccination, a program that has reduced incidence of multiple vaccine-targeted infectious diseas...

China Independent Clinical Laboratory Industry Report, 2019-2025

China's independent clinical laboratory industry is still in its infancy. In 2018, it only saw the penetration rate of about 5%, far below 40% or more in Europe, the United States and Japan. The main ...

Global and China Monoclonal Antibody Industry Report, 2019-2025

Global monoclonal antibody market can be presented as follows: 1. Monoclonal antibody drug market booms and is highly concentrated with the approvals for such drugs.Monoclonal antibody drugs have bee...

China Contract Research Organization (CRO) Industry Report, 2019-2025

The steadily growing global pharmaceutical industry where more and more new drugs have been approved, and the soaring spending on drug research and development in recent years, are a boon for global c...

China Blood Product Industry Report, 2019-2025

With the adjustment of the national medical insurance catalogue, the clinical application and reimbursement rate of almost all blood products have been greatly improved, and the market for blood produ...

China Human Vaccine Industry Report, 2018-2022

As the world’s largest producer of human vaccines, China has established a full-life-cycleregulatory system covering vaccine R&D, production, distribution, and vaccination. The lot release volum...

China Contract Research Organization(CRO) Industry Report, 2017-2021

Under the pressure from higher R&D costs, longer R&D cycle and lower R&D success rate in pharmaceutical industry worldwide, over 50 percent of pharmaceutical enterprises have had the devel...

China Vacuum Blood Collection Device Industry Report, 2017-2021

China’s vacuum blood collection device industry now flourishes after start-up and growth stages. Along with steady improvement in economic environment, rising per-capita disposable income, greater awa...

China Independent Clinical Laboratory Industry Report, 2017-2021

China's independent clinical laboratory industry started late, and is still in its infancy. In 2016, it only saw the penetration rate of about 4%, far below 40% or more in Europe, the United States an...

China Human Vaccine Industry Report, 2017-2021

The human vaccine industry presented the following main characteristics in 2016 in China: 1. Lot release volume of human vaccines declined.Affected by the illegal vaccine case in Mar 2016 in Shandong...

China Independent Clinical Laboratory Industry Report, 2016-2020

Owing to a large population base, uneven distribution of medical resources among regions, aging population, and continuous advance of health care reform, the Chinese independent clinical laboratory ma...

China Human Vaccine Industry Report, 2016-2020

Amid the unsafe domestic vaccine events, China’s human vaccine lot release volume in 2015 fell by 17.9% year on year to only 650 million doses,touching a 5-year low. Moreover, with the improvements in...

China Animal Vaccine Industry Report, 2016-2020

Animal vaccine is a kind of biological agent that enables inoculated animals to produce active immunity for disease prevention. In recent years, European and American animal vaccine markets have seen ...

China Blood Product Industry Report, 2016-2019

Recombinant blood products have developed for many years in foreign countries, but China’s blood products are still proteins extracted from human blood. Thus, reserves and control of plasma resources ...

China Contract Research Organization (CRO) Industry Report, 2015-2018

In recent years, China's contract research organization (CRO) industry has developed rapidly, with the market size rising from RMB8.5 billion in 2007 to RMB42.6 billion in 2014, registering a CAGR of ...

2005- All Rights Reserved 京ICP备05069564号-1 京公网安备1101054484号